Novartis hits targets in late-stage QMF149 asthma trial
The once-daily, fixed-dose treatment demonstrated significant improvements in lung function and asthma control.
Read More
Tag: FEV
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
